@article{randrian:hal-03906999,
TITLE = {FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer},
AUTHOR = {Randrian, Violaine and Pernot, Simon and Le Malicot, Karine and Catena, Vittorio and Baumgaertner, Isabelle and Tacher, Vania and Forestier, Julien and Hautefeuille, Vincent and Tabouret-Viaud, Claire and Gagnaire, Alice and Mitry, Emmanuel and Guiu, Boris and Aparicio, Thomas and Smith, Denis and Dhomps, Anthony and Tasu, Jean-Pierre and Perdrisot, R{\'e}my and Edeline, Julien and Capron, Claude and Cheze-Le Rest, Catherine and Emile, Jean-Fran{\c c}ois and Laurent-Puig, Pierre and Bejan-Angoulvant, Theodora and Sokol, Harry and Lepage, C{\^o}me and Taieb, Julien and Tougeron, David},
URL = {https://hal.sorbonne-universite.fr/hal-03906999},
JOURNAL = {Digestive and Liver Disease},
PUBLISHER = {Elsevier},
VOLUME = {54},
NUMBER = {7},
PAGES = {857-863},
YEAR = {2022},
MONTH = Jul, DOI = {10.1016/j.dld.2022.04.024},
KEYWORDS = {Colorectal cancer ; Immune checkpoint inhibitor ; Liver metastases ; Selective internal radiation therapy},
PDF = {https://hal.sorbonne-universite.fr/hal-03906999/file/Randrian%20et%20al%20-%202022%20-%20FFCD%201709-SIRTCI%20phase%20II%20trial.pdf},
HAL_ID = {hal-03906999},
HAL_VERSION = {v1},
}